Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The update of the guideline on prostate cancer has been and continues to be discussed in all its facets, even with passion.One source of the dispute about some of the content of the current guideline is undoubtedly the lack of precision with which terms were introduced in the past and are still communicated incorrectly and vaguely to this day.In this article, the Professional Association of German Urology (BvDU) discusses five key points with professional policy relevance and where the implementation of the guideline meets the reality of care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00120-025-02662-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.
JAMA Netw Open
September 2025
Department of Urology, Center for Health Outcomes Research and Dissemination, University of Washington, Seattle.
Importance: Black individuals have a twofold higher rate of prostate cancer death in the US compared with the average population with prostate cancer. Few guidelines support race-conscious screening practices among at-risk Black individuals.
Objective: To examine structural factors that facilitate or impede access to prostate cancer screening among Black individuals in the US.
A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer.
JAMA Netw Open
September 2025
Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor.
Importance: Among men with favorable-risk (ie, low-risk or favorable intermediate-risk) prostate cancer, confirmatory testing substantially improves the detection of aggressive cancers that may merit treatment instead of conservative management. Despite guideline recommendations, confirmatory testing is inconsistently used, and more than half of men do not receive it. Value-based interventions and payment incentives may improve care quality by motivating adherence to guideline-concordant care.
View Article and Find Full Text PDFPrescription Trends of Initial Pharmacotherapy for Benign Prostatic Hyperplasia Among Treatment-Naïve Patients in South Korea: A Retrospective Analysis.
Low Urin Tract Symptoms
September 2025
College of Pharmacy, Pusan National University, Busan, Republic of Korea.
Background: Benign prostatic hyperplasia (BPH) is a common urological condition in aging men that causes lower urinary tract symptoms. Pharmacotherapy is central to BPH management; however, considering updated guidelines, recent prescription trends remain insufficiently explored. This study aimed to assess initial pharmacotherapy trends in patients newly diagnosed with BPH.
View Article and Find Full Text PDFSystemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Clinical Insights.
JCO Oncol Pract
September 2025
University of Kansas Medical Center, Westwood, KS.
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
Cancer
September 2025
Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Introduction: Treatment intensification with androgen receptor signaling inhibitors and/or chemotherapy is guideline recommended for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). However, most patients only receive androgen deprivation therapy monotherapy. The aim was to identify physician-, patient-, and tumor-related factors associated with the receipt of treatment intensification.
View Article and Find Full Text PDF